Ascletis to present study results of asc30 oral tablet, asc30 injection, and combination of asc31 and asc47 at obesityweek® 2025

-multiple posters being presented on ascletis' small molecule and peptide obesity programs -full analysis of 28-day multiple ascending dose study of oral glp-1r small molecule agonist asc30 as a late-breaking poster as well as asc30 once-monthly treatment formulation and once-quarterly maintenance formulation hong kong , oct. 27, 2025 /prnewswire/ -- ascletis pharma inc. (hkex: 1672, "ascletis") announces multiple poster presentations of its obesity assets including asc30, and combination of asc31 and asc47 at obesityweek® 2025 in atlanta, georgia. presentation details: abstract title: a full analysis of 28-day mad study of oral glp-1r biased small molecule agonist asc30 for obesity presentation time:  november 4, 2025, 7:30 p.m.
ASC Ratings Summary
ASC Quant Ranking